Intuitive Surgical, Inc. (NASDAQ:ISRG) Stake Lessened by Central Bank & Trust Co.

Central Bank & Trust Co. decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,202 shares of the medical equipment provider’s stock after selling 2,118 shares during the period. Intuitive Surgical accounts for about 1.4% of Central Bank & Trust Co.’s investment portfolio, making the stock its 20th largest holding. Central Bank & Trust Co.’s holdings in Intuitive Surgical were worth $9,925,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hazlett Burt & Watson Inc. boosted its position in shares of Intuitive Surgical by 5.8% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider’s stock valued at $177,000 after purchasing an additional 20 shares in the last quarter. Ullmann Wealth Partners Group LLC lifted its stake in Intuitive Surgical by 1.6% during the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock valued at $653,000 after purchasing an additional 21 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC boosted its holdings in Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after buying an additional 23 shares in the last quarter. Daymark Wealth Partners LLC grew its position in Intuitive Surgical by 0.3% in the third quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock worth $3,452,000 after buying an additional 24 shares during the last quarter. Finally, Indiana Trust & Investment Management CO increased its holdings in shares of Intuitive Surgical by 5.3% in the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after buying an additional 25 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Truist Financial raised their price objective on Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Leerink Partners increased their price target on Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Mizuho upped their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Finally, Wells Fargo & Company lifted their target price on shares of Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a research report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $507.42 on Tuesday. The business has a 50 day simple moving average of $490.97 and a 200 day simple moving average of $448.54. Intuitive Surgical, Inc. has a 52 week low of $269.49 and a 52 week high of $523.34. The stock has a market cap of $180.73 billion, a price-to-earnings ratio of 81.58, a PEG ratio of 4.98 and a beta of 1.39.

Insiders Place Their Bets

In related news, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Gary S. Guthart sold 18,151 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the transaction, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Robert Desantis sold 240 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $464.76, for a total value of $111,542.40. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,558,968.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,246 shares of company stock valued at $33,839,308 over the last ninety days. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.